REGULATORY
JCR’s Sakigake Designated Hunter Syndrome Med Up for PAFSC Review on Feb. 25
A key health ministry panel will review whether to back approval for JCR Pharmaceuticals’ iduronate-2-sulfatase agent pabinafusp alfa at its meeting on Feb 25, together with other new molecular entities (NMEs). If given the green light by the panel, these…
To read the full story
REGULATORY
- Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





